Obesity is a major risk factor for atrial fibrillation. It also influences the natural history of the
disease, leading to more persistent forms and poorer ablation outcomes. This article reviews …

Background Data on the relationship between body mass index (BMI), thromboembolic
events (TEE) and bleeding in patients with atrial fibrillation (AF) are controversial, and further …

Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke,
heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both …

Background Intracranial hemorrhage (ICH) is excluded in most anticoagulation randomized
clinical trials (RCTs), so oral anticoagulant (OAC) therapy is still the conventional treatment …

In the last 40 years, concern about the obesity epidemic has increased. Data from the
current literature highlight a strong relationship between obesity and atrial fibrillation (AF) …

Background: Given the huge burden of atrial fibrillation (AF) and AF-related stroke in Asia,
stroke prevention represents an urgent issue in this region. We herein performed a network …

Abstract Background and Objective Rivaroxaban and apixaban are direct oral
anticoagulants increasing in popularity as convenient alternatives to warfarin. However …

Background: Recent guidelines suggest that, for venous thromboembolism (VTE), standard
doses of apixaban are appropriate in patients with body mass index (BMI)> 40 kg/m2 or> …

This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …

Aim The anticoagulation effect of warfarin is usually evaluated by percentage of time in
therapeutic range (PTTR), which is negatively correlated with the risk of warfarin adverse …